RI-LABELED HUMANIZED ANTIBODY

RI-LABELED HUMANIZED ANTIBODY

The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the aforementioned radionuclide is a metal nuclide emitting α particle or positron, and the aforementioned antibody is a humanized antibody specifi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TAKAYUKI MURAKAMI, NOBUYA KOBASHI, NORIHITO NAKATA, YASUSHI OCHIAI, YOSHINARI SHOYAMA, MITSUHIRO MATONO
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator TAKAYUKI MURAKAMI
NOBUYA KOBASHI
NORIHITO NAKATA
YASUSHI OCHIAI
YOSHINARI SHOYAMA
MITSUHIRO MATONO
description The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the aforementioned radionuclide is a metal nuclide emitting α particle or positron, and the aforementioned antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ZA202205226B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ZA202205226B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ZA202205226B3</originalsourceid><addsrcrecordid>eNrjZJAN8tT1cXRy9XF1UfAI9XX084wCshz9Qjyd_F0ieRhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJfJSjkYGRkYGpkZGZkzExagCFRiD0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>RI-LABELED HUMANIZED ANTIBODY</title><source>esp@cenet</source><creator>TAKAYUKI MURAKAMI ; NOBUYA KOBASHI ; NORIHITO NAKATA ; YASUSHI OCHIAI ; YOSHINARI SHOYAMA ; MITSUHIRO MATONO</creator><creatorcontrib>TAKAYUKI MURAKAMI ; NOBUYA KOBASHI ; NORIHITO NAKATA ; YASUSHI OCHIAI ; YOSHINARI SHOYAMA ; MITSUHIRO MATONO</creatorcontrib><description>The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the aforementioned radionuclide is a metal nuclide emitting α particle or positron, and the aforementioned antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.</description><language>eng</language><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231129&amp;DB=EPODOC&amp;CC=ZA&amp;NR=202205226B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231129&amp;DB=EPODOC&amp;CC=ZA&amp;NR=202205226B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TAKAYUKI MURAKAMI</creatorcontrib><creatorcontrib>NOBUYA KOBASHI</creatorcontrib><creatorcontrib>NORIHITO NAKATA</creatorcontrib><creatorcontrib>YASUSHI OCHIAI</creatorcontrib><creatorcontrib>YOSHINARI SHOYAMA</creatorcontrib><creatorcontrib>MITSUHIRO MATONO</creatorcontrib><title>RI-LABELED HUMANIZED ANTIBODY</title><description>The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the aforementioned radionuclide is a metal nuclide emitting α particle or positron, and the aforementioned antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJAN8tT1cXRy9XF1UfAI9XX084wCshz9Qjyd_F0ieRhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJfJSjkYGRkYGpkZGZkzExagCFRiD0</recordid><startdate>20231129</startdate><enddate>20231129</enddate><creator>TAKAYUKI MURAKAMI</creator><creator>NOBUYA KOBASHI</creator><creator>NORIHITO NAKATA</creator><creator>YASUSHI OCHIAI</creator><creator>YOSHINARI SHOYAMA</creator><creator>MITSUHIRO MATONO</creator><scope>EVB</scope></search><sort><creationdate>20231129</creationdate><title>RI-LABELED HUMANIZED ANTIBODY</title><author>TAKAYUKI MURAKAMI ; NOBUYA KOBASHI ; NORIHITO NAKATA ; YASUSHI OCHIAI ; YOSHINARI SHOYAMA ; MITSUHIRO MATONO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ZA202205226B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>TAKAYUKI MURAKAMI</creatorcontrib><creatorcontrib>NOBUYA KOBASHI</creatorcontrib><creatorcontrib>NORIHITO NAKATA</creatorcontrib><creatorcontrib>YASUSHI OCHIAI</creatorcontrib><creatorcontrib>YOSHINARI SHOYAMA</creatorcontrib><creatorcontrib>MITSUHIRO MATONO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TAKAYUKI MURAKAMI</au><au>NOBUYA KOBASHI</au><au>NORIHITO NAKATA</au><au>YASUSHI OCHIAI</au><au>YOSHINARI SHOYAMA</au><au>MITSUHIRO MATONO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>RI-LABELED HUMANIZED ANTIBODY</title><date>2023-11-29</date><risdate>2023</risdate><abstract>The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the aforementioned radionuclide is a metal nuclide emitting α particle or positron, and the aforementioned antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_ZA202205226B
source esp@cenet
title RI-LABELED HUMANIZED ANTIBODY
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A32%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TAKAYUKI%20MURAKAMI&rft.date=2023-11-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EZA202205226B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true